Skip NavigationSkip to Content

NCI at Frederick Scientific Publications Advanced Search

Search

  1. NCI-F Publications

  2. Return to Quick Search
Search
  2. Year Published:

Your search returned 23 results.
User Information
Export Records
  1. 1.   BETA: a comprehensive benchmark for computational drug-target prediction
  2. Zong, Nansu; Li,Ning; Wen, Andrew; Ngo, Victoria; Yu, Yue; Huang, Ming; Chowdhury, Shaika; Jiang, Chao; Fu, Sunyang; Weinshilboum, Richard; Jiang, Guoqian; Hunter, Lawrence; Liu, Hongfang
  3. Briefings in Bioinformatics. 2022, Jun 02;
  1. 2.   Naturally Occurring Canine Melanoma as a Predictive Comparative Oncology Model for Human Mucosal and Other Triple Wild-Type Melanomas
  2. Hernandez, Belen; Adissu, Hibret A.; Wei, Bih; Michael, Helen T.; Merlino, Glenn; Simpson, R. Mark
  3. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES. 2018, FEB; 19
  1. 3.   A simple device to convert a small-animal PET scanner into a multi-sample tissue and injection syringe counter
  2. Green, Michael V.; Seidel, Jurgen; Choyke, Peter L.; Jagoda, Elaine M.
  3. NUCLEAR MEDICINE AND BIOLOGY. 2017, Oct; 53: 9-13.
  1. 4.   Bridging the Gap: Moving Predictive and Prognostic Assays from Research to Clinical Use
  2. Williams, P. M.; Lively, T. G.; Jessup, J. M.; Conley, B. A.
  3. Clinical Cancer Research. 2012, Mar; 18(6): 1531-1539.
  1. 5.   Ribose) Polymerase Inhibitor ABT-888 in Human Peripheral Blood Mononuclear Cells
  2. Ji, J. P.; Kinders, R. J.; Zhang, Y. P.; Rubinstein, L.; Kummar, S.; Parchment, R. E.; Tomaszewski, J. E.; Doroshow, J. H.
  3. Plos One. 2011, Oct; 6(10): 8.
  1. 6.   Anti-HIV microbicide development: targeting the virus is the key
  2. O'Keefe, B. R.
  3. Future Virology. 2011, May; 6(5): 553-556.
  1. 7.   Development of a Validated Immunofluorescence Assay for gamma H2AX as a Pharmacodynamic Marker of Topoisomerase I Inhibitor Activity
  2. Kinders, R. J.; Hollingshead, M.; Lawrence, S.; Ji, J. P.; Tabb, B.; Bonner, W. M.; Pommier, Y.; Rubinstein, L.; Evrard, Y. A.; Parchment, R. E.; Tomaszewski, J.; Doroshow, J. H.; Natl Canc Inst Phase 0 Clinical, T.
  3. Clinical Cancer Research. 2010, Nov; 16(22): 5447-5457.
  1. 8.   The statistics of phase 0 trials
  2. Rubinstein, L. V.; Steinberg, S. M.; Kummar, S.; Kinders, R.; Parchment, R. E.; Murgo, A. J.; Tomaszewski, J. E.; Doroshow, J. H.
  3. Statistics in Medicine. 2010, May; 29(10): 1072-1076.
  1. 9.   MONICA: a compact, portable dual gamma camera system for mouse whole-body imaging
  2. Xi, W. Z.; Seidel, J.; Kakareka, J. W.; Pohida, T. J.; Milenic, D. E.; Proffitt, J.; Majewski, S.; Weisenberger, A. G.; Green, M. V.; Choyke, P. L.
  3. Nuclear Medicine and Biology. 2010, Apr; 37(3): 245-253.
  1. 10.   Guidelines for the Development and Incorporation of Biomarker Studies in Early Clinical Trials of Novel Agents
  2. Dancey, J. E.; Dobbin, K. K.; Groshen, S.; Jessup, J. M.; Hruszkewycz, A. H.; Koehler, M.; Parchment, R.; Ratain, M. J.; Shankar, L. K.; Stadler, W. M.; True, L. D.; Gravell, A.; Grever, M. R.; Biomarkers Task Force, N. C. I. I.
  3. Clinical Cancer Research. 2010, Mar; 16(6): 1745-1755.
  1. 11.   Response: Re: Antitumor Efficacy Testing in Rodents
  2. Hollingshead, M. G.
  3. Journal of the National Cancer Institute. 2009 101(22): 1593-1594.
  1. 12.   Phase 0 Clinical Trial of the Poly (ADP-Ribose) Polymerase Inhibitor ABT-888 in Patients With Advanced Malignancies
  2. Kummar, S.; Kinders, R.; Gutierrez, M. E.; Rubinstein, L.; Parchment, R. E.; Phillips, L. R.; Ji, J. P.; Monks, A.; Low, J. A.; Chen, A.; Murgo, A. J.; Collins, J.; Steinberg, S. M.; Eliopoulos, H.; Giranda, V. L.; Gordon, G.; Helman, L.; Wiltrout, R.
  3. Journal of Clinical Oncology. 2009 27(16): 2705-2711.
  1. 13.   Oncologic phase 0 trials incorporating clinical pharmacodynamics: from concept to patient
  2. Doroshow, J. H.; Parchment, R. E.
  3. Clinical Cancer Research. 2008 14(12): 3658-3663.
  1. 14.   Antitumor Efficacy Testing in Rodents
  2. Hollingshead, M. G.
  3. Journal of the National Cancer Institute. 2008 100(21 DI 10.1093/jnci/d):
  1. 15.   Phase 0 clinical trials: Conceptions and misconceptions
  2. Kummar, S.; Rubinstein, L.; Kinders, R.; Parchment, R. E.; Gutierrez, M. E.; Murgo, A. J.; Ji, J.; Mroczkowski, B.; Pickeral, O. K.; Simpson, M.; Hollingshead, M.; Yang, S. X.; Helman, L.; Wiltrout, R.; Collins, J.; Tomaszewski, J. E.; Doroshow, J. H.
  3. Cancer Journal. 2008 14(3): 133-137.
  1. 16.   Designing phase 0 cancer clinical trials
  2. Murgo, A. J.; Kummar, S.; Rubinstein, L.; Gutierrez, M.; Collins, J.; Kinders, R.; Parchment, R. E.; Ji, J.; Steinberg, S. M.; Yang, S. X.; Hollingshead, M.; Chen, A.; Helman, L.; Wiltrout, R.; Tomaszewski, J. E.; Doroshow, J. H.
  3. Clinical Cancer Research. 2008 14(12): 3675-3682.
  1. 17.   Accelerated preclinical testing using transplanted tumors from genetically engineered mouse breast cancer models
  2. Varticovski, L.; Hollingshead, M. G.; Robles, A. I.; Wu, X. L.; Cherry, J.; Munroe, D. J.; Lukes, L.; Anver, M. R.; Carter, J. P.; Borgel, S. D.; Stotler, H.; Bonomi, C. A.; Nunez, N. P.; Hursting, S. D.; Qiao, W. H.; Deng, C. X. X.; Green, J. E.; Hunter, K. W.; Merlino, G.; Steeg, P. S.; Wakefield, L. M.; Barrett, J. C.
  3. Clinical Cancer Research. 2007, Apr; 13(7): 2168-2177.
  1. 18.   International collaboration in drug discovery and development from natural sources
  2. Cragg, G. M.; Newman, D. J.
  3. Pure and Applied Chemistry. 2005, NOV; 77(11): 1923-1942.
  1. 19.   Cytotoxicity of RH1: NAD(P)H : quinone acceptor oxidoreductase (NQO1)-independent oxidative stress and apoptosis induction
  2. Tudor, G.; Alley, M.; Nelson, C. M.; Huang, R. L.; Covell, D. G.; Gutierrez, P.; Sausville, E. A.
  3. Anti-Cancer Drugs. 2005 16(4): 381-391.
  1. 20.   Taking aim at a moving target: designing drugs to inhibit drug-resistant HIV-1 reverse transcriptases
  2. Sarafianos, S. G.; Das, K.; Hughes, S. H.; Arnold, E.
  3. Current Opinion in Structural Biology. 2004, DEC; 14(6): 716-730.
  1. 21.   A potential role for imaging technology in anticancer efficacy evaluations
  2. Hollingshead, M. G.; Bonomi, C. A.; Borgel, S. D.; Carter, J. P.; Shoemaker, R.; Melillo, G.; Sausville, E. A.
  3. European Journal of Cancer. 2004 40(6): 890-898.
  1. 22.   Diminished hepatocellular proliferation in mice humanized for the nuclear receptor peroxisome proliferator-activated receptor alpha
  2. Cheung, C.; Akiyama, T. E.; Ward, J. M.; Nicol, C. J.; Feigenbaum, L.; Vinson, C.; Gonzalez, F. J.
  3. Cancer Research. 2004 64(11): 3849-3854.
  1. 23.   Tumor endothelial markers: new targets for cancer therapy
  2. Nanda, A.; St Croix, B.
  3. Current Opinion in Oncology. 2004, JAN; 16(1): 44-49.
NCI at Frederick

You are leaving a government website.

This external link provides additional information that is consistent with the intended purpose of this site. The government cannot attest to the accuracy of a non-federal site.

Linking to a non-federal site does not constitute an endorsement by this institution or any of its employees of the sponsors or the information and products presented on the site. You will be subject to the destination site's privacy policy when you follow the link.

ContinueCancel